Kevin Urdahl, M.D., Ph.D., joined the Institute this month as the third principal investigator in our tuberculosis research program. In addition to the drug discovery research already underway at Seattle BioMed, Dr. Urdahl’s lab, which brings expertise in immunology, has their sights set on the development of a new, more effective TB vaccine. Read more
